Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/signaling.2.032
HK2 fuels anoikis resistance to accelerate ICC metastasis
Xiaojing Du1, Sunkuan Hu2,*
- 1Endoscopy Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
- 2Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
Corresponding Author
Sunkuan Hu, xhnkhsk@wzhospital.cn
Received Date: March 29, 2024
Accepted Date: April 24, 2024
Du X, Hu S. HK2 fuels anoikis resistance to accelerate ICC metastasis. Cell Signal. 2024;2(1):71-73.
Copyright: © 2024 Du X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Probes for cancer metastasis imaging and therapeutic targeting
Metastasis of cancer is the process by which the primary tumor spreads from the original site to other parts of the body. Palliative care is the most common treatment option available for patients with metastatic cancer, but most patients eventually succumb to the disease due to the lack of therapeutics that can specifically target disseminated tumors [1].
HK2 fuels anoikis resistance to accelerate ICC metastasis
Intrahepatic cholangiocarcinoma (ICC), the second most frequent primary liver tumor, is a highly metastatic malignancy and often leads to disaster outcome in majority of patients, bringing significant challenges in the medical field [1].
FBXOing down V-ATPase: Implications for combating cancer metastasis
FBXO9, an evolutionarily conserved member of the F-box protein family, functions as a substrate receptor within the Cullin 1-RING ubiquitin ligase complex (CRL1), also known as the SKP1-Cullin 1-F-box (SCF) complex [1].
How to inhibit breast cancer and breast cancer metastasis with Akt inhibitors: Lessons learned from studies in mice
The PI3K/Akt signaling pathway is frequently hyperactivated in different types of breast cancer. In the past two decades, major efforts have been made to develop inhibitors of this pathway to treat cancer patients.
Metastatic breast cancer-derived exosomes and osteoclast-mediated bone metastasis
The progress of bone metastases mainly depends upon the interaction among the cells of the bone microenvironment such as endothelial cells, hematopoietic stem cells (HSCs), mesenchymal stromal cells (MSCs), immune cells and bone cells [bone-forming osteoblasts (OBs) and bone-resorbing OCs], strengthening the growth, migration, dormancy and reactivation of metastatic BC cells [7]